Takeda Pharmaceutical (TYO:4502) and BioSurfaces said today that the two companies inked a deal to develop novel medical devices intended to treat patients with gastrointestinal diseases. The deal brings together Takeda’s experience in the gastroenterology space and BioSurfaces’ method of developing nanomaterials from FDA-approved polymers for medical implants and drug-delivery devices. Financial terms of the deal were not […]
Takeda Pharmaceuticals
Aptar Pharma’s nasal spray compliance device wins EMA nod
Aptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company. The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals […]
Takeda, Cognition Kit launch pilot of wearable cognitive software for assessing MDD
Takeda (TYO:4502) said today it is collaborating with Cambridge Cognition Holdings and Ctrl Group Ltd joint Cognition Kit to pilot study of a specially designed Apple (NSDQ:AAPL) Watch application to assess cognitive function in patients with major depressive disorder. The Cognition Kit is designed to assess cognitive symptoms in patients with MDD and move patient care […]
TiGenix, Takeda highlight data for cell therapy in patients with Chron’s disease
Takeda (TYO:4502) and TiGenix (EBR:TIG) today touted long-term data from its phase III Admire-CD trial evaluating its suspension of allogenic expanded adipose-derived stem cells, Cx601, in patients with Chron’s disease. The study showed that Cx601 maintained long-term remission of treatment refractory complex perianal fistulas over 52 weeks. The randomized, phase III trial compared Cx601 to […]
TiGenix IPO raises $36m
TiGenix (EBR:TIG) said today that it raised $36 million in an initial public offering from the sale of 2.3 million American depository shares, representing 46 million ordinary shares, at $15.50 apiece. The biopharmaceutical company plans to list on the NASDAQ exchange under the “TIG” symbol by Dec. 15. It is listed on the Euronext Brussels under the same symbol. […]
Takeda looks to wearables for IBD patients
Takeda Pharmaceuticals (TYO:4502) yesterday launched a wearable watch pilot program to help people suffering with inflammatory bowel disease track their symptoms. Takeda said they will roll out the program, iBData, with 100 patients tracking their daily symptoms and lifestyle factors. Then, the data is collected into a report that is shared with the patient’s doctor, […]
Toshiba Medical Systems enters the race for Takeda’s chemicals subsidiary
Toshiba Medical Systems, the medical device business Toshiba (TYO:6502) is selling to Canon (NYSE:CAJ) for $6.5 billion, reportedly entered the race to acquire a chemicals subsidiary of Takeda Pharmaceutical (TYO:4502). The Nikkei business daily reported today that Takeda is looking to sell its 70% stake in Osaka-based Wako Pure Chemicals Industries, with the 1st round of bidding closing August 16. Toshiba Medical is competing […]
